Lexeo Therapeutics, Inc.
lexeotx.comWhat Do They Do?
Develops genetic-medicine candidates, including gene therapies for inherited heart diseases, for patients with cardiovascular conditions.
10-K for FY2025, filed Mar 30, 2026We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change…View ↗
We are developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have high unmet…View ↗
We are developing LX2006 as an AAVrh10-based gene therapy delivered intravenously for the treatment of FA cardiomyopathy. LX2006 is…View ↗
LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$25.9MView ↗
- ▼ −1% (Loss)
- vs −$26.1M in Q2 FY2025
-
Aug 12, 2026
Reported second-quarter 2026 results and clinical program updates
The company said it began its pivotal SUNRISE-FA 2 study and expects topline data in the second half of 2027.
Sources
8-K, filed Aug 12, 2026
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data…View ↗
Who Do They Compete With?
Competes with Solid Biosciences, Voyager Therapeutics, Neurocrine Biosciences, Larimar Therapeutics, PTC Therapeutics, Biogen, Rocket Pharmaceuticals, and Tenaya Therapeutics
10-K for FY2025, filed Mar 30, 2026We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target.…View ↗
Loading...
